Advertisement
Screener

Standard BioTools Inc. (LAB) Increase (Decrease) in Other Operating Liabilities

2.8 / 5 stars · 68/120 Roast Me

Standard BioTools Inc. Increase (Decrease) in Other Operating Liabilities

Standard BioTools Inc. (LAB) reported Increase (Decrease) in Other Operating Liabilities of -$6.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-05

  • Standard BioTools Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was -$7.00K, a 117.50% decline year-over-year.
  • Standard BioTools Inc. increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was $1.00K, a 99.03% decline year-over-year.
  • Standard BioTools Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was -$378.00K, a 251.81% decline year-over-year.
  • Standard BioTools Inc. increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was $27.00K, a 200.00% increase year-over-year.
  • Standard BioTools Inc. increase (decrease) in other operating liabilities for fiscal 2025 was -$208.00K.
  • Standard BioTools Inc. increase (decrease) in other operating liabilities for fiscal 2024 was -$4.18M, a 9002.13% decline from fiscal 2023.
  • Standard BioTools Inc. increase (decrease) in other operating liabilities for fiscal 2023 was $47.00K.
  • Standard BioTools Inc. increase (decrease) in other operating liabilities for fiscal 2022 was -$5.98M.
Period endIncrease (Decrease) in Other Operating Liabilities 3 monthIncrease (Decrease) in Other Operating Liabilities 3 month as first filedIncrease (Decrease) in Other Operating Liabilities 6 monthIncrease (Decrease) in Other Operating Liabilities 6 month as first filedIncrease (Decrease) in Other Operating Liabilities 9 monthIncrease (Decrease) in Other Operating Liabilities 9 month as first filedIncrease (Decrease) in Other Operating Liabilities 12 monthIncrease (Decrease) in Other Operating Liabilities 12 month as first filed
2026-06-30-$7.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
-$6.00K
10-Q · filed 2026-08-05
-$384.00K
derived: sum of 3 quarters · filed 2026-08-05
-$357.00K
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$1.00K
10-Q · filed 2026-05-06
-$377.00K
derived: sum of 2 quarters · filed 2026-05-06
-$350.00K
derived: sum of 3 quarters · filed 2026-05-06
-$310.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$378.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
-$351.00K
derived: sum of 2 quarters · filed 2026-03-16
-$311.00K
derived: sum of 3 quarters · filed 2026-08-05
-$208.00K
10-K · filed 2026-03-16
2025-09-30$27.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$67.00K
derived: sum of 2 quarters · filed 2026-08-05
$170.00K
10-Q · filed 2025-11-04
$419.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$40.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$143.00K
10-Q · filed 2026-08-05
$392.00K
derived: sum of 3 quarters · filed 2026-08-05
$401.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$103.00K
10-Q · filed 2026-05-06
$352.00K
derived: sum of 2 quarters · filed 2026-05-06
$361.00K
derived: sum of 3 quarters · filed 2026-05-06
$372.00K
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$249.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$258.00K
derived: sum of 2 quarters · filed 2026-03-16
$269.00K
derived: sum of 3 quarters · filed 2026-03-16
-$4.18M
10-K · filed 2026-03-16
2024-09-30$9.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$20.00K
derived: sum of 2 quarters · filed 2025-11-04
-$4.43M
10-Q · filed 2025-11-04
-$4.43M
derived: sum of 4 quarters · filed 2026-03-16
2024-06-30$11.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15
-$4.44M
10-Q · filed 2025-08-15
-$4.44M
derived: sum of 3 quarters · filed 2026-03-16
-$5.55M
derived: sum of 4 quarters · filed 2026-03-16
2024-03-31-$4.45M
10-Q · filed 2025-05-06
-$4.45M
derived: sum of 2 quarters · filed 2026-03-16
-$5.56M
derived: sum of 3 quarters · filed 2026-03-16
-$4.56M
derived: sum of 4 quarters · filed 2026-03-16
2023-12-31$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
-$1.11M
derived: sum of 2 quarters · filed 2026-03-16
-$107.00K
derived: sum of 3 quarters · filed 2026-03-16
$47.00K
10-K · filed 2026-03-16
$3.21M
10-K · filed 2024-03-01
2023-09-30-$1.11M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
-$108.00K
derived: sum of 2 quarters · filed 2024-11-06
$46.00K
10-Q · filed 2024-11-06
$4.13M
10-Q · filed 2023-11-07
-$149.00K
derived: sum of 4 quarters · filed 2025-03-11
2023-06-30$1.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$1.16M
10-Q · filed 2024-08-06
$963.00K
derived: sum of 3 quarters · filed 2025-03-11
-$218.00K
derived: sum of 4 quarters · filed 2025-03-11
2023-03-31$154.00K
10-Q · filed 2024-05-09
$198.00K
10-Q · filed 2023-05-09
-$41.00K
derived: sum of 2 quarters · filed 2025-03-11
-$1.22M
derived: sum of 3 quarters · filed 2025-03-11
-$4.48M
derived: sum of 4 quarters · filed 2025-03-11
2022-12-31-$195.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
-$1.38M
derived: sum of 2 quarters · filed 2025-03-11
-$4.63M
derived: sum of 3 quarters · filed 2025-03-11
-$5.98M
10-K · filed 2025-03-11
2022-09-30-$1.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
-$4.44M
derived: sum of 2 quarters · filed 2023-11-07
-$5.78M
10-Q · filed 2023-11-07
-$8.56M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30-$3.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
-$4.60M
10-Q · filed 2023-08-08
-$7.38M
derived: sum of 3 quarters · filed 2023-08-08
-$11.51M
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31-$1.35M
10-Q · filed 2023-05-09
-$4.12M
derived: sum of 2 quarters · filed 2023-05-09
-$8.26M
derived: sum of 3 quarters · filed 2023-05-09
-$7.17M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31-$2.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14
-$6.91M
derived: sum of 2 quarters · filed 2023-03-14
-$5.83M
derived: sum of 3 quarters · filed 2023-03-14
-$10.80M
10-K · filed 2023-03-14
2021-09-30-$4.13M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$3.05M
derived: sum of 2 quarters · filed 2022-11-09
-$8.02M
10-Q · filed 2022-11-09
$1.62M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30$1.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$3.88M
10-Q · filed 2022-08-09
$5.75M
derived: sum of 3 quarters · filed 2022-08-09
$5.87M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$4.97M
10-Q · filed 2022-05-09
-$9.99M
10-Q · filed 2021-05-07
$4.67M
derived: sum of 2 quarters · filed 2022-05-09
$4.79M
derived: sum of 3 quarters · filed 2022-05-09
$2.56M
derived: sum of 4 quarters · filed 2022-05-09
2020-12-31$9.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
$9.75M
derived: sum of 2 quarters · filed 2022-03-08
$7.53M
derived: sum of 3 quarters · filed 2022-03-08
$5.46M
10-K · filed 2022-03-08
$14.09M
10-K · filed 2021-02-25
2020-09-30$117.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
-$2.11M
derived: sum of 2 quarters · filed 2021-11-09
-$4.17M
10-Q · filed 2021-11-09
-$180.00K
10-Q · filed 2020-11-09
$5.65M
derived: sum of 4 quarters · filed 2022-03-08
2020-06-30-$2.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06
-$4.29M
10-Q · filed 2021-08-06
-$2.80M
10-Q · filed 2020-08-07
$5.53M
derived: sum of 3 quarters · filed 2022-03-08
$4.19M
derived: sum of 4 quarters · filed 2022-03-08
2020-03-31-$2.07M
10-Q · filed 2021-05-07
$7.76M
derived: sum of 2 quarters · filed 2022-03-08
$6.41M
derived: sum of 3 quarters · filed 2022-03-08
$8.11M
derived: sum of 4 quarters · filed 2022-03-08
2019-12-31$9.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
$8.48M
derived: sum of 2 quarters · filed 2022-03-08
$10.17M
derived: sum of 3 quarters · filed 2022-03-08
-$681.00K
10-K · filed 2022-03-08
-$11.35M
10-K · filed 2020-02-27
2019-09-30-$1.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$346.00K
derived: sum of 2 quarters · filed 2020-11-09
-$10.51M
10-Q · filed 2020-11-09
2019-06-30$1.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
-$9.16M
10-Q · filed 2020-08-07
2019-03-31-$10.85M
10-Q · filed 2020-05-11
2018-12-31-$4.64M
10-K · filed 2021-02-25
2017-12-31$1.36M
10-K · filed 2020-02-27
2016-12-31$580.00K
10-K · filed 2019-03-18
$620.00K
10-K · filed 2017-03-03
2015-12-31-$4.02M
10-K · filed 2018-03-08
-$3.99M
10-K · filed 2016-02-29
2014-12-31-$1.54M
10-K · filed 2017-03-03
2014-03-31$1.55M
10-Q · filed 2014-05-12
$3.89M
derived: sum of 2 quarters · filed 2016-02-29
$5.36M
derived: sum of 3 quarters · filed 2016-02-29
$5.30M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$2.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$3.81M
derived: sum of 2 quarters · filed 2016-02-29
$3.74M
derived: sum of 3 quarters · filed 2016-02-29
$3.99M
10-K · filed 2016-02-29
2013-09-30$1.47M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07
$1.41M
derived: sum of 2 quarters · filed 2013-11-07
$1.65M
10-Q · filed 2013-11-07
$3.01M
derived: sum of 4 quarters · filed 2015-02-26
2013-06-30-$65.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
$181.00K
10-Q · filed 2013-08-07
$1.54M
derived: sum of 3 quarters · filed 2015-02-26
$2.24M
derived: sum of 4 quarters · filed 2015-02-26
2013-03-31$246.00K
10-Q · filed 2014-05-12
-$939.00K
10-Q · filed 2013-05-09
$1.60M
derived: sum of 2 quarters · filed 2015-02-26
$2.30M
derived: sum of 3 quarters · filed 2015-02-26
$1.53M
derived: sum of 4 quarters · filed 2015-02-26
2012-12-31$1.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26
$2.06M
derived: sum of 2 quarters · filed 2015-02-26
$1.28M
derived: sum of 3 quarters · filed 2015-02-26
$1.79M
10-K · filed 2015-02-26
2012-09-30$698.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07
-$74.00K
derived: sum of 2 quarters · filed 2013-11-07
$433.00K
10-Q · filed 2013-11-07
$1.14M
derived: sum of 4 quarters · filed 2014-03-12
2012-06-30-$772.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
-$265.00K
10-Q · filed 2013-08-07
$437.00K
derived: sum of 3 quarters · filed 2014-03-12
$321.00K
derived: sum of 4 quarters · filed 2014-03-12
2012-03-31$507.00K
10-Q · filed 2013-05-09
$1.21M
derived: sum of 2 quarters · filed 2014-03-12
$1.09M
derived: sum of 3 quarters · filed 2014-03-12
$1.46M
derived: sum of 4 quarters · filed 2014-03-12
2011-12-31$702.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12
$586.00K
derived: sum of 2 quarters · filed 2014-03-12
$953.00K
derived: sum of 3 quarters · filed 2014-03-12
-$24.00K
10-K · filed 2014-03-12
2011-09-30-$116.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09
$251.00K
derived: sum of 2 quarters · filed 2012-11-09
-$726.00K
10-Q · filed 2012-11-09
-$340.00K
derived: sum of 4 quarters · filed 2013-03-12
2011-06-30$367.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14
-$610.00K
10-Q · filed 2012-08-14
-$224.00K
derived: sum of 3 quarters · filed 2013-03-12
$830.00K
derived: sum of 4 quarters · filed 2013-03-12
2011-03-31-$977.00K
10-Q · filed 2012-05-15
-$591.00K
derived: sum of 2 quarters · filed 2013-03-12
$463.00K
derived: sum of 3 quarters · filed 2013-03-12
2010-12-31$386.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12
$1.44M
derived: sum of 2 quarters · filed 2013-03-12
$1.96M
10-K · filed 2013-03-12
2010-09-30$1.05M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14
$1.57M
10-Q · filed 2011-11-14
2010-06-30$516.00K
10-Q · filed 2011-08-09
2009-12-31$1.07M
10-K · filed 2012-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01